OncoGenex Pharmaceuticals (NASDAQ: ACHV) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.
Volatility & Risk
OncoGenex Pharmaceuticals has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 2.86, meaning that its share price is 186% more volatile than the S&P 500.
Valuation & Earnings
This table compares OncoGenex Pharmaceuticals and Ionis Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|OncoGenex Pharmaceuticals||$5.06 million||3.61||-$20.12 million||($3.11)||-0.49|
|Ionis Pharmaceuticals||$346.62 million||19.16||-$86.55 million||$0.15||354.82|
OncoGenex Pharmaceuticals has higher earnings, but lower revenue than Ionis Pharmaceuticals. OncoGenex Pharmaceuticals is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
3.3% of OncoGenex Pharmaceuticals shares are held by institutional investors. Comparatively, 91.4% of Ionis Pharmaceuticals shares are held by institutional investors. 35.8% of OncoGenex Pharmaceuticals shares are held by insiders. Comparatively, 2.1% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares OncoGenex Pharmaceuticals and Ionis Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for OncoGenex Pharmaceuticals and Ionis Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Ionis Pharmaceuticals has a consensus target price of $50.92, suggesting a potential downside of 4.33%. Given Ionis Pharmaceuticals’ higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than OncoGenex Pharmaceuticals.
Ionis Pharmaceuticals beats OncoGenex Pharmaceuticals on 11 of the 13 factors compared between the two stocks.
OncoGenex Pharmaceuticals Company Profile
Achieve Life Sciences, Inc., formerly OncoGenex Pharmaceuticals, Inc., is a clinical-stage pharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company’s product candidates include Custirsen, Cytisine and OGX-225. These products are designed to block the production of specific proteins that promotes treatment resistance and survival of tumor cells, and are over-produced in response to a variety of cancer treatments. The Company is focused on targeting these particular proteins to disable the tumor cell’s adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company’s subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.
Receive News & Ratings for OncoGenex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.